Skip to main content
. 2022 Aug 31;8(35):eabn9550. doi: 10.1126/sciadv.abn9550

Fig. 4. NDI1 normalizes labeling in TCA cycle intermediates following IACS-010759 treatment.

Fig. 4.

(A) Fractional enrichment normalized to tumor glucose m+6 in SK-N-AS subcutaneous xenografts expressing NDI1 or a control vector (EV) and treated with DMSO or IACS-010759 (EV: DMSO, n = 5 and IACS-010759, n = 6; NDI1: DMSO, n = 6 and IACS-010759, n = 5). (B) Citrate m+2/pyruvate m+3 ratio in xenografts expressing EV or NDI1 and treated with DMSO or IACS-010759. (C) Citrate m+3/pyruvate m+3 ratio in xenografts expressing EV or NDI1 and treated with DMSO or IACS-010759. (D) Western blot showing expression of Mito-LbNOX in SK-N-AS cells. (E) NAD+/NADH ratio in cultured SK-N-AS cells expressing either EV or Mito-LbNOX and treated with DMSO or IACS-010759. (F) Citrate m+2/pyruvate m+3 ratios in xenografts expressing EV or Mito-LbNOX and treated with DMSO or IACS-010759. Statistical significance was assessed using one-way ANOVA followed by Sidak’s multiple comparisons adjustment (A to C) or by unpaired Student’s t test (D and E). Data represent means ± SD (A to C) or SEM (E and F).